Spero Therapeutics Inc. (SPRO)
NASDAQ: SPRO
· Real-Time Price · USD
0.66
0.00 (0.30%)
At close: May 01, 2025, 3:59 PM
0.65
-1.52%
After-hours: May 01, 2025, 04:08 PM EDT
0.30% (1D)
| Bid | 0.63 |
| Market Cap | 36.89M |
| Revenue (ttm) | 33.05M |
| Net Income (ttm) | -68.57M |
| EPS (ttm) | -1.27 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | -1.27 |
| Analyst | Hold |
| Ask | 0.7 |
| Volume | 26,828 |
| Avg. Volume (20D) | 169,850 |
| Open | 0.67 |
| Previous Close | 0.66 |
| Day's Range | 0.66 - 0.68 |
| 52-Week Range | 0.51 - 1.72 |
| Beta | 0.64 |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct actin...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 2, 2017
Employees 32
Stock Exchange NASDAQ
Ticker Symbol SPRO
Website https://sperotherapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for SPRO stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 657.58% from the latest price.
Stock ForecastsNext Earnings Release
Spero Therapeutics Inc. is scheduled to release its earnings on May 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
-1.53%
Spero Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
6 months ago
+1.55%
Spero Therapeutics shares are trading lower after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.
